vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update
vTv Therapeutics Inc. - Class A (VTVT)
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vtvtherapeutics.com
Company Research
Source: GlobeNewswire
HIGH POINT, N.C., July 31, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019, and provided an update on recent achievements and upcoming events. “We made significant progress during the second quarter,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “We reported positive results from part 1 of our phase 2 Simplici-T1 trial in type 1 diabetes and began screening patients for our 488-305 trial evaluating azeliragon in patients with mild Alzheimer’s disease and type 2 diabetes. We look forward to continuing to execute successfully on our development plans for each of these drug candidates and advancing them as potential treatments for patients suffering from these diseases.” Recent Achievements and Outlook Part 1 of the Simplici-T1 Study achieves positive topline results in patients with type 1 diabetes. In June 2019, we announced positive topline results from part 1 of the p
Show less
Read more
Impact Snapshot
Event Time:
VTVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTVT alerts
High impacting vTv Therapeutics Inc. - Class A news events
Weekly update
A roundup of the hottest topics
VTVT
News
- vTv Therapeutics Inc. (NASDAQ: VTVT) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $35.00 price target on the stock.MarketBeat
- CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCERPR Newswire
- vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]Yahoo! Finance
- vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx ConferenceGlobeNewswire
- Diabetes Pipeline Landscape Research Report 2024: Comprehensive Insights About 200+ Companies and 200+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
VTVT
Sec Filings
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- 11/19/24 - Form 4
- VTVT's page on the SEC website